Precision medicine, which considers the genetics of the tumor tissues and cells for selection of the most appropriate treatment strategy, has recently been developed for colorectal cancer. The BRAF mutation status in colorectal cancer has been tested, but precision medicine for BRAF-mutated tumors had not been applicable due to no approved BRAF-targeting drugs until recently. In addition, conventional standard chemotherapy for BRAF-mutated colorectal cancer show limited effectiveness, resulting in poor prognosis. Therefore, we need new drugs specific for BRAF-mutated colorectal cancer. In this review, we outline the characteristics, development, and new treatment strategies for BRAF-mutated colorectal cancer. In addition, we introduce the BEACON CRC study, which prospectively evaluated the efficacy and safety of combination therapy of encorafenib(BRAF inhibitor), binimetinib(MEK inhibitor), and cetuximab(anti-EGFR antibody)in patients with metastatic colorectal cancer with the BRAF V600E-mutation.Cancer patients often have oral complications during cancer therapies that can be followed by various systemic complications. If these oral complications remain untreated and worsen, cancer treatment has to be postponed or suspended. In recent years, the importance of oral supportive care for cancer patients has been recognized and that medical-dental collaboration is the key to solving these problems. Close cooperation between medical and dental professionals will prevent oral complications, and so treatment can continue without delay or hindrance. Also, the quality of life of the cancer patient can be improved. Many current anticancer drug treatments are performed as outpatient treatments. However, the number of dentists working in hospitals is small and it is difficult for them to manage all cancer patients. Therefore, oral supportive care in hospital dentistry is not sufficient and patients have to see a local dentist. It is highly recommended that the patient has a "family dentist"and undergo regular oral examinations and dental care. In Japan, the Japan Dental Association has established a regional dentist cooperation system to seamlessly provide appropriate oral supportive care to cancer patients. The policy is to provide patients with continuous oral supportive care not only before the start of treatment, but also during and after treatment. In addition, hospital professionals and family dentists work together to exchange information and provide support and dental care for oral problems, depending on the status of cancer treatment and the needs of the patient.Regarding regional cooperation in palliative care for advanced cancer, the problem is complicated by the fact that the 3 factors of hospital circumstances, regional circumstances, and the patient's own wishes are different. Depending on the hospital, the patient can be seen to the end, the palliative care resources are different depending on the region, and the patient's own wishes also change depending on the time. When considering the characteristic trajectory that a cancer patient will follow to the end, it is essential to prepare early, but what is important here is a double primary care physician system consisting of a cancer therapist and palliative care. However, in communication when introducing palliative care, it is important to consider the timing and the feeling that the patient has been abandoned. This period is an important point for patients, how to spend the end of their lives, and it is desirable to think carefully about how to approach it according to the region. Palliative care is not only medical care for dying, but also medical care that supports how to live at the end of life.We conducted a questionnaire survey of cancer patients and medical institutions to examine the usage status and problems of the regional cooperation critical pathway (cooperation path). In a survey of medical institutions, 65% of respondents said that using a cooperation path was beneficial, which was a significant increase from the previous survey in 2014. According to a survey on workload, about 30% of doctors felt that the workload increased in 2018 as well as in 2014. On the other hand, hospital profits increased at twice as many medical institutions compared to 2014. https://www.selleckchem.com/products/halofuginone.html According to surveys of cancer patients, 80% of patients said that they were happy to use the cooperation path. However, a small percentage of patients disagreed with the use of the cooperation path. In this questionnaire survey, it was found that not only doctors but also patients understand the merits of the cooperation path.Based on the basic plan to promoting cancer control programs, a cooperation between designated cancer care hospitals and regional medical institutions was outlined. Regional designated cancer care hospitals supports the system of regional cancer medical treatment cooperation, and prefectural designated cancer care hospital manage a prefectural cancer medical treatment cooperation. Although system is progressing, such as sharing regional cooperation pass and holding multi-facility joint meetings to promote regional cooperation, there are regional disparities, and we believe that further promotion is necessary.Armed antibodies, of which are representative antibody-drug conjugate(ADC)and radioimmunotherapy(RIT), are attracting attention as next-generation antibody drugs with high efficacy and low side effects. Armed antibodies require clinically optimized adaptation and development strategies, in addition to the fusion of basic technologies such as organic chemistry, protein chemistry, imaging technology, structural biology, and biomarker research. In armed antibodies, the antibody is only a carrier for deliver and its therapeutic effect affects the specificity/strength of the payload, which is the effector agent for target molecules on cell surface. An ADC with a bystander effect is a promising drug for solid tumors with heterogeneous target molecule expression. Aside from the next-generation ADC DS8201, new ADCs are being developed at an accelerated pace, demonstrating new therapeutic possibilities. In the future, it will be necessary to optimize predictors of therapeutic effect based on the MOA of ADC.